gv20-0251
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2023 (NCT05669430)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Testicular Neoplasms · Phase 1
Mechanism of action
- Immunoglobulin superfamily member 8INHIBITOR
IGSF8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07106827 | Phase 1 | Sep 4, 2025 | GV20 Therapeutics, Sichuan University |
| NCT07070518 | Phase 1/Phase 2 (Phase 2) | Jul 11, 2025 | GV20 Therapeutics |
| NCT05669430 | Phase 1 | Feb 15, 2023 | GV20 Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GV20 Therapeutics | For profit | 3 | 2 | 2 | 2023 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1